The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

• The Alzheimer's Disease Drug Development Pipeline: Observations and Implications, AD/PD™ Session Spotlight

  In this episode of AD/PD™ Session Spotlight, we present Plenary Lecture 1 from AD/PD™ 2025, titled "The Alzheimer's Disease Drug Development Pipeline: Observations and Implications," delivered by Dr. Jeffrey Cummings (USA) and chaired by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden).Renowned for his leadership in Alzheimer’s research, Dr. Cummings offers a sweeping and data-driven overview of the evolving landscape of Alzheimer’s drug development—spotlighting trends, challenges, and opportunities shaping the future of treatment.Key highlights include:• A record 182 active trials involving 138 unique drug candidates, reflecting unprecedented momentum in the pipeline• The rising importance of biomarkers across all trial phases, from early discovery to outcome measurement• A growing focus on inflammation and immunity as therapeutic targets• Insights into global trial dynamics, including site participation, recruitment hurdles, and regional disparities• The role of repurposed drugs and innovative trial designs in accelerating progress• A look ahead at anticipated readouts from ongoing trials, and what they may mean for patients and providersThis episode is highly relevant for drug developers, clinical trial professionals, regulatory stakeholders, and anyone invested in the future of Alzheimer's treatment, offering a clear-eyed perspective on where the field is headed—and why it matters.This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.https://adpd.kenes.com/

  --------  

  15:05
• Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies, AD/PD™ Session Spotlight

  In episode 2 of AD/PD™ Session Spotlight, we feature Plenary Lecture 3, the Don Price Memorial Lecture, titled "Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies," presented by Prof. Charlotte Teunissen (The Netherlands) and chaired by Dr. Sangram Sisodia (USA).This compelling lecture honors the legacy of Dr. Donald L. Price and explores the transformative role of plasma biomarkers in Alzheimer’s disease care, from diagnosis to personalized treatment strategies.Key highlights include:• The clinical readiness of plasma biomarkers like P-tau217 for diagnosing and monitoring Alzheimer’s disease• Insights from ongoing implementation studies in the Netherlands and international efforts to standardize biomarker use• The role of biomarkers in predicting treatment response, tracking cognitive change, and identifying molecular subtypes• Emerging technologies, such as proteomics, and their use in developing predictive biomarker panels• New frontiers in biomarker discovery, including alpha-synuclein seed aggregation assays and dopamine decarboxylase for detecting co-pathologiesThis episode is essential for neurologists, clinical researchers, biomarker scientists, and healthcare professionals aiming to integrate biomarkers into routine dementia care and tailor treatments in the era of disease-modifying therapies.This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.https://adpd.kenes.com/

  --------  

  17:14
• Varying Regulatory Philosophies and AD Approval Priorities, AD/PD™ Session Spotlight

  In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approaches impact the development, approval, and accessibility of Alzheimer’s disease therapies.Co-moderated by Agneta Nordberg (Sweden) and David Holtzman (USA), this discussion brings together insights from international regulatory and clinical experts: Naohiro Egawa (Japan), Tamara Shiner (Israel), Henrik Zetterberg (Sweden), and Pavel Balabanov (The Netherlands).Key highlights include:• The complex landscape of disease-modifying drug approvals, exemplified by the case of kinumab• Contrasts in regulatory frameworks between the EMA, FDA, and Japan’s PMDA• The evolving role of biomarkers in diagnosis and treatment selection• Ongoing challenges in balancing risk, clinical utility, and access across diverse healthcare systemsThis episode is a must-listen for global stakeholders in Alzheimer’s research, regulation, and clinical care, looking to navigate the nuances of regional policy and foster cross-border collaboration in advancing neurodegenerative disease treatments.This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.https://adpd.kenes.com/

  --------  

  18:03
• Welcome to the AD/PD™ Session Spotlight

  Welcome to AD/PD™ Session Spotlight, an official podcast series by AD/PD™. The podcast will discuss the latest cutting-edge science and real-world clinical impact in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases, presented at the AD/PD™ 2025 Conference.This AI-generated series is built for medical professionals and researchers who want to stay current with the latest breakthroughs without missing a step. Each episode offers concise, curated summaries of key sessions from the AD/PD™ 2025 Conference in Vienna. From novel therapies and biomarker discovery to translational research and trial data, we’ll spotlight the science that’s moving the field forward.Whether you’re joining us in person or tuning in from your lab, clinic, or office, this podcast brings the heart of the Conference directly to you.Powered by AI. Driven by science.AD/PD™ 2025 took place April 1–5, 2025 in Vienna, Austria.For more information visit https://adpd.kenes.comExplore year-round learning with AD/PD™ Education on UNLOK: https://unlok-education.com/ad-pd/

  --------  

  1:38

Mais podcasts de Ciência

Podcasts em tendência em Ciência

Sobre The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases